Market Currents
Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in...
-
Monday, June 4, 2012, 1:28 PM ETBristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK).
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
